Drug Trial Radar · NCT06762054
Investigating the Optimal Management of Dolutegravir Resistance
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6,624
Actual
Start
Mar 3, 2025
Primary completion
Feb 15, 2027
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- University of NairobiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Instituto Nacional de Saúde, Mozambique; Muhimbili University of Health and Allied Sciences; SolidarMed; London School of Hygiene and Tropical Medicine
- First posted
- Jan 7, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to address the gap in published data on viral suppression among people meeting the criteria for virologic failure on dolutegravir (DTG)-based ART regimens without a change in regimen. The study will also assess the emergence of DTG-associated drug-resistant mutations and their impact on viral suppression.
Conditions
- HIV-1-infection
Interventions
Continue DTG-based antiretroviral therapyDrug
Participants will continue on DTG-based ART after enrollment for up to 24 months
Enhanced adherence counsellingBehavioral
Participants with VL ≥200 copies/mL will undergo enhanced adherence counselling
Primary outcomes
What the sponsor says the trial is designed to measure.
- Viral suppression rateTime frame: 12 months
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Jaramogi Oginga Odinga Teaching and Referral Hospital
Kisumu, Kenya
Bomu Hospital
Mombasa, Kenya
Kenyatta National Hospital
Nairobi, Kenya
Butha-Buthe District Hospital
Butha-Buthe, Lesotho
Mokhotlong District Hospital
Mokhotlong, Lesotho
CS Machava II
Maputo, Mozambique
CS Ndlavela
Maputo, Mozambique
CS Ponta Gea
Beira, Sofala, Mozambique
MUHAS Clinical Trial Unit
Dar es Salaam, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.